| Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models I Keklikoglou, C Cianciaruso, E Güç, ML Squadrito, LM Spring, ... Nature cell biology 21 (2), 190-202, 2019 | 466 | 2019 |
| CD95/Fas, non-apoptotic signaling pathways, and kinases M Le Gallo, A Poissonnier, P Blanco, P Legembre Frontiers in immunology 8, 1216, 2017 | 81 | 2017 |
| CD95-mediated calcium signaling promotes T helper 17 trafficking to inflamed organs in lupus-prone mice A Poissonnier, D Sanséau, M Le Gallo, M Malleter, N Levoin, R Viel, ... Immunity 45 (1), 209-223, 2016 | 79 | 2016 |
| Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation A Poissonnier, JP Guégan, HT Nguyen, D Best, N Levoin, G Kozlov, ... Nature chemical biology 14 (12), 1079-1089, 2018 | 25 | 2018 |
| Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases M Farhat, A Poissonnier, A Hamze, C Ouk-Martin, JD Brion, M Alami, ... Cell Death & Disease 5 (5), e1201-e1201, 2014 | 15 | 2014 |
| Tumor analysis: freeze–thawing cycle of triple-negative breast cancer cells alters tumor CD24/CD44 profiles and the percentage of tumor-infiltrating immune cells M Le Gallo, T de la Motte Rouge, A Poissonnier, V Lavoué, P Tas, ... BMC Research Notes 11, 1-20, 2018 | 8 | 2018 |
| Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis HT Nguyen, JP Guégan, A Poissonnier, F Jouan, D Best, P van de Weghe, ... Bioorganic & medicinal chemistry letters 29 (16), 2094-2099, 2019 | 3 | 2019 |
| Boyden chamber assay to study of cell migration induced by metalloprotease cleaved-CD95L A Poissonnier, P Legembre CD95: Methods and Protocols, 117-123, 2017 | 3 | 2017 |
| From tumor progression to therapeutic control: Combinatorial targeting of immune vulnerabilities in TNBC A Poissonnier, EV Egeland, W Horton, S Sivagnanam, O Stapleton, ... Cancer Research 84 (6_Supplement), 4027-4027, 2024 | | 2024 |
| Th2 infiltration is a better predictor of survival than tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC) S Brousse, F Godey, P Tas, B Campillo-Gimenez, E Lafont, A Poissonnier, ... medRxiv, 2023.06. 02.23289891, 2023 | | 2023 |
| Relieving immune suppressive pathways in breast cancer to improve outcomes A Poissonnier, EV Egeland, R Erbe, W Horton, A Howells-Ferreira, ... Cancer Research 83 (7_Supplement), 4164-4164, 2023 | | 2023 |
| Tumor-Infiltrating Myeloid Cells in Cancer Progression and Therapy Response LM Kumar, Sushil | Poissonnier, Amanda | Betts, Courtney B. | Murugan ... Cancer Immunotherapy Principles and Practice 2, DOI: 10.1891/9780826137432.0034, 2021 | | 2021 |
| Relieving immune suppressive pathways in breast cancer to improve outcomes. A Poissonnier, D Murugan, W Horton, T Cotechini, HS Rugo, ... CANCER IMMUNOLOGY RESEARCH 8 (4), 39-40, 2020 | | 2020 |
| Abstract A03: Relieving immune suppressive pathways in breast cancer to improve outcomes A Poissonnier, D Murugan, W Horton, T Cotechini, HS Rugo, ... Cancer Immunology Research 8 (4_Supplement), A03-A03, 2020 | | 2020 |
| Methods and pharmaceutical compositions for reducing cd95-mediated cell motility P Legembre, P Vacher, A Poissonnier, P Blanco | | 2019 |
| HIV protease inhibitors and autoimmunity: An odd, but promising idea G Galli, A Poissonnier, JP Guégan, M Charrier, V Sisirak, E Lazaro, ... Autoimmunity Reviews 18 (10), 102370, 2019 | | 2019 |
| HIV Protease Inhibitors Cure Lupus-Prone Mice and Prevent T Helper 17 Cell-Driven Inflammation By Inhibiting CD95-Non-Apoptotic Signaling Pathway M Charrier, A Poissonnier, D Best, JP Guégan, N Levoin, R Pineau, ... Arthritis & rheumatology 70 (suppl 10), 2018 | | 2018 |
| Signalisation CD95/CD95L: implications dans le Lupus Erythémateux Systémique et développement d'outils thérapeutiques ciblés A Poissonnier Rennes 1, 2017 | | 2017 |
| T cell landscape in triple negative breast cancer patients A Poissonnier, M Le Gallo, F Godey, P Legembre Breast 32, S99--S99, 2017 | | 2017 |
| Atypical Immune Functions of CD95/CD95L A Poissonnier, P Legembre TRAIL, Fas Ligand, TNF and TLR3 in Cancer, 131-157, 2017 | | 2017 |
